Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine
Trial Start Expected In August-October
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.
